Deal or Case news
NautaDutilh Luxembourg assisted Pharmathen, a leading European complex drug delivery and formulation developer, on its acquisition of CBL Patras, a leading vertically integrated peptides developer and US-FDA approved manufacturer and supplier in Europe.

Pharmathen has developed one of the most advanced pipelines of long-acting injectables, sustained-release oral solids, and ophthalmic formulations, produced in its US-FDA and EU-approved manufacturing facilities in Greece. The acquisition serves to reinforce Pharmathen’s position in the global peptide therapeutics market, currently estimated at EUR 38 billion.

CBL Patras is one of the key peptide material suppliers in Europe. Established in 1990 by Professor Dr. Kleomenis Barlos, the Barlos family will continue to work closely with Pharmathen and CBL, to solidify the integrated businesses on a global scale and accommodate necessary expansion.

Assisting Pharmathen on this acquisition was a rewarding experience.
Caroline Notté, Corporate M&A partner

Caroline Notté, NautaDutilh’s Corporate M&A partner who led the deal, commented: "Assisting Pharmathen on this acquisition, alongside the London team of Ropes & Gray, was a rewarding experience. The NautaDutilh team was happy to participate in this transaction which opens doors for Pharmathen to broaden its product range for customers and, importantly, enhances access to affordable medicines.”

The team further consisted of senior associate Brice Bertolotti and associates Armin Klüter and Antonio Marin from our Corporate M&A practice.

Related articles

Cookie notification

This functionality uses third-party cookies. Change your cookie preferences to view this content or view more information.
These cookies ensure that the website works properly. These cookies cannot be disabled.
These cookies can be placed by third parties, such as YouTube or Vimeo.
By deactivating categories, it is possible that related functionalities within the website may no longer work properly. It is always possible to change your preferences at a later time. View more information.